The latest dementia headlines rest on a few hard numbers: an estimated 7.2 million Americans age 65 and older now live with Alzheimer's dementia, and two amyloid-targeting drugs have won full FDA approval. Dementia means a loss of memory and thinking severe enough to disrupt daily life; Alzheimer's disease is its most common cause. This analysis walks through the figures behind those headlines—how many people are affected, what the new treatments actually deliver, and what the coverage rules mean for a family deciding what to do next. The goal is to separate the measurable facts from the marketing.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How big is the dementia burden right now?
- What do the newly approved drugs actually do?
- What are the real risks and the latest dosing changes?
- Who qualifies, and what does it cost?
- Turning the numbers into a next step
- Frequently Asked Questions
How big is the dementia burden right now?
In 2025, Alzheimer's dementia crossed 7 million cases in the 65-plus U.S. population for the first time. The Alzheimer's Association 2025 Facts and Figures report puts the number at 7.2 million and projects 13.8 million by 2060, driven mainly by an aging population. risk climbs sharply with age rather than evenly.
Among people 65 to 74, about 5% have Alzheimer's dementia; that rises to 13.2% for ages 75 to 84 and 33.4% for those 85 and older, according to the same peer-reviewed prevalence data. In practical terms, one in three of the oldest Americans is affected. The caregiving load is the number that often gets buried. Nearly 12 million Americans provide unpaid dementia care, contributing more than 19 billion hours in 2024—work the Alzheimer's Association values above $413 billion, on top of a projected $384 billion in national care costs for 2025.
What do the newly approved drugs actually do?
Two drugs anchor the treatment headlines: donanemab (brand name Kisunla) and lecanemab (Leqembi). Both are antibody infusions that clear amyloid, a sticky protein that builds up in the brains of people with Alzheimer's. Neither cures the disease or reverses damage. The FDA granted Kisunla traditional approval on July 2, 2024, per Eli Lilly's announcement, for adults in the early symptomatic stage—mild cognitive impairment or mild dementia—with confirmed amyloid buildup.
It is not approved for moderate or advanced disease. The benefit is a slowdown, not a stop. In the Phase 3 TRAILBLAZER-ALZ 2 trial, donanemab slowed decline by 35% versus placebo in the least-advanced group, and 22% across the overall study population, measured on a combined cognitive-and-function scale. That means the disease still progresses—just somewhat more slowly.
What are the real risks and the latest dosing changes?
The most important caveat carries the FDA's strongest warning. Kisunla's label includes a Boxed Warning for amyloid-related imaging abnormalities, or ARIA—brain swelling and small bleeds that can be serious or even life-threatening. The Lilly label requires MRI monitoring before and during treatment. Regulators have responded to that risk with dosing tweaks.
In 2025 the FDA approved a modified titration schedule for Kisunla, shown to reduce the rate of ARIA-E (the swelling form) in early Alzheimer's disease, as described in the updated-label announcement. Lecanemab is following a similar convenience path. On August 29, 2025, the FDA approved Leqembi IQLIK, a once-weekly under-the-skin autoinjector for maintenance dosing, with a U.S. launch on October 6, 2025, according to Eisai. That shifts some patients from clinic infusions toward at-home injections—but the underlying ARIA risk and monitoring needs remain.
Who qualifies, and what does it cost?
Eligibility and coverage are tightly linked, so start there before scheduling anything. Medicare Part B covers lecanemab and donanemab only under specific conditions, and Leqembi runs about $26,500 per year before coverage.
The Alzheimer's Association's coverage summary lists three requirements that must all be met: That registry step is easy to overlook and can stall access. You can review the exact rules in the CMS coverage and registry decision memo before an appointment, so you arrive knowing which tests and paperwork your clinic must complete.
- Confirmed amyloid pathology, verified by a PET scan or spinal fluid test
- A diagnosis of mild cognitive impairment or mild dementia—not a later stage
- Enrollment in a CMS-approved data registry that tracks real-world outcomes
Turning the numbers into a next step
Match the statistics to your own situation instead of the headline average. If the person you care for is in the early symptomatic stage with confirmed amyloid, the approved drugs are worth a specific conversation with a neurologist; if the disease is moderate or advanced, these treatments are not indicated and the discussion should center on care and safety. A practical sequence keeps the decision grounded:.
- Get an accurate staging diagnosis, since eligibility hinges on "early" versus later disease
- Ask directly about ARIA risk, MRI schedule, and what the 22–35% slowdown means for daily life
- Confirm Medicare registry enrollment and out-of-pocket cost before the first infusion
Frequently Asked Questions
Do the new drugs stop or reverse Alzheimer's?
No. Donanemab and lecanemab slow decline—by roughly 22% to 35% in donanemab's trial—but the disease still progresses and existing damage is not reversed.
Why does age matter so much in the statistics?
Prevalence jumps from about 5% at ages 65–74 to 33.4% at 85 and older, so risk is concentrated among the oldest adults rather than spread evenly.
What is ARIA, and why the monitoring?
ARIA is amyloid-related brain swelling or bleeding tied to these drugs. It can be serious, so the FDA requires MRI scans before and during treatment.
